Hepion interim CEO buys stock and warrants
Hepion Pharmaceuticals, Inc. reporting person Gary S. Stetz, Interim CEO and director, reported two purchases on August 3, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Hepion Pharmaceuticals, Inc. reporting person Gary S. Stetz, Interim CEO and director, reported two purchases on August 3, 2026. He acquired 2,000,000 warrants, each exercisable at $0.06 per share into common stock until August 3, 2031. He also purchased 2,000,000 shares of common stock at $0.05 per share, bringing his directly held common stock position to 3,250,000 shares.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 4,000,000 shares
Net Buy
2 txns
Insider
Stetz Gary S.
Role
Interim CEO
Bought
4,000,000 shs ($100K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Warrants | 2,000,000 | $0.00 | $0.00 |
| Purchase | Common Stock | 2,000,000 | $0.05 | $100K |
Holdings After Transaction:
Warrants — 2,000,000 contracts (Direct);
Common Stock — 3,250,000 shares (Direct)
Key Figures
Common shares purchased: 2,000,000 shares
Purchase price per common share: $0.05
Common shares held after transaction: 3,250,000 shares
+3 more
6 metrics
Common shares purchased
2,000,000 shares
Common stock purchase on August 3, 2026 at $0.05 per share
Purchase price per common share
$0.05
Price paid for 2,000,000 common shares on August 3, 2026
Common shares held after transaction
3,250,000 shares
Direct ownership of common stock following August 3, 2026 purchase
Warrants acquired
2,000,000 warrants
Derivative securities acquired on August 3, 2026
Warrant exercise price
$0.06 per share
Exercise price for warrants into Hepion common stock
Warrant expiration date
August 3, 2031
Expiration of 2,000,000 warrants acquired on August 3, 2026
Key Terms
Warrants, derivative, exercise price, expiration date
4 terms
Warrants financial
"security_title: "Warrants" and underlying_security_title: "Common Stock""
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
derivative financial
"transaction_type: "derivative" for the warrant acquisition entry"
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
exercise price financial
"conversion_or_exercise_price: "0.0600" as the warrant exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2031-08-03" for the warrants acquired"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Hepion Pharmaceuticals (HEPA) report for Gary S. Stetz?
Gary S. Stetz reported two purchases on August 3, 2026: 2,000,000 warrants and 2,000,000 shares of Hepion Pharmaceuticals common stock in open market or private transactions.
What are the terms of the warrants bought by Gary S. Stetz of Hepion Pharmaceuticals (HEPA)?
Gary S. Stetz acquired 2,000,000 warrants on August 3, 2026. Each warrant has an exercise price of $0.06 per share, is exercisable into common stock, and carries an expiration date of August 3, 2031.
At what prices did Gary S. Stetz buy Hepion Pharmaceuticals (HEPA) securities?
On August 3, 2026, Gary S. Stetz purchased 2,000,000 common shares at $0.05 per share and acquired 2,000,000 warrants with an exercise price of $0.06 per underlying share.
Is the Hepion Pharmaceuticals (HEPA) Form 4 transaction under a Rule 10b5-1 plan?
The filing indicates the Rule 10b5-1 checkbox is not affirmed (set to false), so the reported August 3, 2026 transactions are not identified as made under a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates